Skip to content

Platelet-Rich Plasma Injection for Chronic Scrotal Content Pain: A Prospective Open-Label Pilot Study

Safety and Feasibility of Activated Platelet Rich Plasma Injection for Chronic Scrotal Content Pain: A Prospective Open-Label Pilot Study - nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/114204
Enrollment
15
Registered
2026-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N51- Disorders of male genital organs in diseases classified elsewhere

Interventions

Intervention1: Autologous Platelet-Rich Plasma: Injection of platelet-rich plasma in the scrotum around the spermatic cord. Two-injection protocol will be employed: Injection site one with 3 mL of a

Sponsors

AIIMS Raipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male patients aged 18 to 60 years. 2. Chronic scrotal content pain involving the testis, epididymis, or spermatic cord persisting for 3 months or more. 3. Localized tenderness over the spermatic cord and or paratesticular structures on clinical examination. 4. Positive diagnostic spermatic cord block, defined as equal to or more than 50 percent temporary pain relief, indicating peripheral cord mediated pain. 5. Scrotal ultrasonography excluding surgically correctable pathology, with findings not requiring immediate operative intervention.

Exclusion criteria

Exclusion criteria: 1. Evidence of central sensitization or referred pain, including predominant lumbar spine, hip, or abdominal pathology contributing to symptoms. 2. Active genitourinary infection, testicular malignancy, or suspicious scrotal lesion. 3. Untreated varicocele or other surgically correctable cause of scrotal pain. 4. Prior microsurgical denervation of the spermatic cord or other definitive nerve-ablative procedures. 5. Coagulation disorders, platelet dysfunction, or current anticoagulant therapy that cannot be safely discontinued.

Design outcomes

Primary

MeasureTime frame
Incidence of procedure related adverse events infection, hematoma, worsening pain, testicular atrophyTimepoint: at intervention, 3-month, and 6-month follow-up

Secondary

MeasureTime frame
1. Change in pain intensity measured by Visual Analog Scale at baseline, 1 month, 3 months, and 6 months 2. Reduction in analgesic medication usage: Proportion of patients achieving equal or more than 50 percent reduction in analgesic medication use 3. Patient global impression of improvement PGI-I Timepoint: at baseline, 1 month, 3 months, and 6 months

Countries

India

Contacts

Public ContactSatyadeo Sharma

AIIMS Raipur

satyadeo2004@gmail.com7772967744

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026